TAPBP

TAP binding protein, the group of C1-set domain containing

Basic information

Region (hg38): 6:33299694-33314284

Links

ENSG00000231925

∙ NCBI:6892 ∙ OMIM:601962 ∙ HGNC:11566 ∙ Uniprot:O15533 ∙ AlphaFold ∙ GenCC ∙ jax ∙ Sfari ∙ GnomAD ∙ Pubmed ∙ ClinVar

Phenotypes

GenCC

Source: genCC

MHC class I deficiency (Limited), mode of inheritance: AR
MHC class I deficiency (Supportive), mode of inheritance: AR
MHC class I deficiency (Limited), mode of inheritance: AR
MHC class I deficiency (Moderate), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

Condition	Inheritance	Intervention Categories	Intervention/Rationale	Manifestation Categories	References
MHC class I deficiency 3	AR	Allergy/Immunology/Infectious	Although the described individual did not have the same types of infections as other individuals with TAP deficiency, antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial	Allergy/Immunology/Infectious	10074495; 12149238

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the TAPBP gene.

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the TAPBP gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type	Pathogenic	Likely pathogenic	VUS	Likely benign	Benign	Sum
synonymous				66 clinvar	6 clinvar	72
missense			135 clinvar	11 clinvar	2 clinvar	148
nonsense			5 clinvar			5
start loss			1 clinvar			1
frameshift			9 clinvar			9
inframe indel			2 clinvar			2
splice donor/acceptor (+/-2bp)			2 clinvar			2
splice region			3	5	1	9
non coding				13 clinvar	5 clinvar	18
Total	0	0	154	90	13

Variants in TAPBP

This is a list of pathogenic ClinVar variants found in the TAPBP region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position	Phenotype	Significance	ClinVar
6-33301762-A-C	MHC class I deficiency	Uncertain significance (Jan 30, 2020)	2436954
6-33301775-G-T	MHC class I deficiency	Likely benign (Dec 11, 2023)	1105304
6-33302502-TTTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGCTGGTCTTGAACTCCTGACCTCAGGTGATCCGCCCTCCTCAGCCTCCCAAAGTGCTAGGATTACAGGCGTGAACCAACGCACCTGGCCAAGACTGTAATTTCTTTTTCTTTTTTTTTTGTTGTTGAGACGAAGTTTTCCTTTTGTCACCCAGGCTGGAGTGCAATGGTGTGATCTCAGCTCACTGCAACCTCTGCCTCCCAGGTTCAAGCGATTCTCCTGCCCCAGTCTCCCGAGTAGCTGGGATTACAGGTGCCGTCACATCTGGCTAATTTTTTGTATTTTTAGTAGAGATGGGGTTTCATCATGTTGGCTAAGCTGGTCTTGAACTCCTGACCTCAGGTGATCCTCCCGCCTCGGCCTCCCAAAGTGCAGGGATTACAGGCATGAGCCATCGCACCCGGCCTGTAATTTCTTATATTGTTTACATGTTGCAATAATATTTTGGATGTACAGGTTGAGCATCGCCGATCCAAAACTCTAAAATCTGAAATGTTCCAAAACCTGAAATTTTTTTAGTGCCAACATGATGCCACAAGTGGAAAATCCCACAGCTGCCCTCATGTGATGGGTCACATATATTATTAAAAATATTGTGGTCGGGTGCAGCGGTTCACACCTGTAATCCCAACGCTTTGGGAGGCCAAGGCAGCGGGCGGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCCAGGCGTGGTGGTGGGTGCCTGTAATCCCAACTACTCGGGAGGCTAAGGCAGGAGAATCGCTTGAACCTGGGAGGTGGAGGTTGCAGTGAGCCGAGATCGCACCATTGCACCCCAGCCTGGGCGACAGAGACTCTGTCTCAAAAAAAAAGAGAAGGAAAAAAATCTTCAGGCCATGTGTATAAGGTGTATAGGAAACATAAATGATTTCTGTGTTTAGATTTGGGTCTGATCCCAAAGATATTAAATATATGCAAATATTCCAAAGTCTGAAAAAATCCAACATCCAAAAACACTTCTGACCCAAGCATTTCAGATAAGGGACCAGAATTATTAGATTAAATAAGGTATATTATTAAGTTAATTTTACCTGTTTCTGCTTATTTTTTTAATGTGAGTACTAGAGTATTTAAATTTACATATGTGGCTTGCATTATCTTTCTATTGGACAGCACTGCCTAAGTAACTTTTTAAAATCCCTACACCCAAGGAAACATATAGATTAAGTAGCATGCTCAAAGAGTCCTACAGTTAGGATATAGTGCCAGGTTTTAACCCAGATCAGTGTGAATTCCAAGCCTAGGTTCTGCCTACCACACCAGCAGCCTCCCTCCATGGGTTTTGAGATAGGATGAGGAGATAAAGTGACAAGGGAAAGATACAGAGAGGTGGAGCACTGTACCTTCTTTGAATCCTTGCAGGTGGACAGGTAGACAGCTGTGGGGAAAGATTGAGAAGGGATGGGATGCTGGAGTGGTAGAGGTGGAGGGCAGAGGGATGGGTGTCAGGCTCTTGGGAGTAGGTGGGGAAAGTCCACCAACCTCAGGTCATGGTCAGGGTAGGGCTGACACTTACCAGCCCAGCCCAGTGCCTTGAAGAGCCCAAGCAGAAGAAAGGCAGACAGGAAAAGGCCTACGCTGTCCTCAAGGGAGGGCCCTGAAAGACCTGGCAGGCAGAAGGGGTGAGAGTGAGCTCCTGTCTTCCTGGGTGCTGGCTCAGATTCCGCAGAGCTCCCAGCTCTTACCTGCTACCTCCAGGGTGACCTCAGCGCTGCGCCCCGAGGCAGGCAGGCTGGGATGGTGAATTCGACAGGCATAGCGTGCCCCATGCTGCTCAGTGGTGACTGGGGGCGGCTGCAAGTGCCCAGAGAGGCTGACAGAGCCATCGGAATGGTGGCGCAGGGCCGAGAGCCACCTCTGCCCCTCGGCCTTCTGAGAGCGGCCCCCTGGGCCACCCCGGAGTTCCCACTCCACCTCCAGGCCCCCAGAAGGGTAGAAGTGGGACACAAGGCAGAGCAATTCCGGGGGTGCCTCCCCTGGGGCGGCCCGTGCAAGGGTTGCTGGCATCAGGGACACTTTGGGGGGTTCTGGGGAAAGAGGACGAAATGAGCATAGGGAAATCAGTCCATACTGTCCTCCCTAAGAGACCCTCAGTTTGCCTGCTGGCTTCCTCAGAACTAAAGAAGGTTAGGTTTCTTCTCCTGAAATAGGGAACCCACTGTCTCTCCATTGGTGCGTCACAGAAATACCCATGTCAAAGCCCCTCAAATTTCCAGGAAACTTCTAGCCTCCCATTACCCCTCTAACTCCCAGGAACCTCTTTCTATCTCTACTTACTTGCCCAGGCACCCTCTTATCCATCATCCCTCCCCCTATTACGGTCCCCACAATCCAGTGCCCACCCTCTACCCCTGGAGACCTCTGTCCCCCAACTCACTGTACACAGCAAGCTCCAGGGTGACCTGTCCTTGCAGGTATGGCAGGTGTATGGTGGCCAGATAGGTGCCCTCCTGAAAGGGTTGAACTGTAGGCAGCCAGAAGGTCCCATTTCCGGTCCATGGGCCCCATGGCTCATCATCATCCCAAGCAGCAAATGCCACGGCCCCTTCTTGGGCTGCTGGCATCTGGCCATTCAGCCCAGGAGTTGCAGCCAGGAGCAGATGTCCCTTACCCAGGTGCTGGCGTCGCCACTCTAGCCCAAAGGGAGGGGGACCCGGAGCCAGAGATGAGGCGGCCTCGGAGGTGGGGGGCATGTAGGCAAAGCTCAAGTCCAGCAGAGCATCTTGTCCCAGTCTCACTCGAGGGGCAGGGGTGTGGGTGAGGACAGTCAGTACCACTGAGGAAGACAGGGAGATGAGGGGTTGGGAGGGGCATGAGGGAGAGAAAGAAGGAGAAAAAAATAGAGAAATGCAGTTATTGGGGAGGGCTAAACTGCAGTTTACCCACCCCTCAGAGGACACCTTTTCTGATACTCACCATTTCCTAGCCCTCCCTGCAAACTCCTTTTGCTCTGCGACTGGGTGGCACCTAGTGTGGCTGAGGGTGAGCAGAGAGGTCTAGGGGTGGTGAGTAGGGGCAATGAGGGGGTATGGCCTTTGAAGCCTACTCTGAACACATAGCACACTCTAGCTCGGGGGACTGCAGAATCCGAGGCCACTTCTGACACAACCTGAACCACTCTATCTCCAAGCACCACCCTTGAGGAACCAGGCCTTTCTTGATTACAGGCGAAGACAATGATTGAGCCATGACTGTCAGTCTTGTGGTGCTGTACAGAATATTTACTGACTCTAGAAGGTTCCAGCTCTAGCCTAGACCTGAGCACAGACCTCTATGCTCTACTGAAGCAGTACAGTGCAGTGGCTAAGTGCCTGGAGCCTGGCTGACCGGGTTCAAATCCCCTCTGCAGCTTATTTATATGGCCTTGGGCCACTTCCTTTTTCCATGGCTCAGCTTCCTAATCTCTAAAATTAAAAGTTGATGATAATAATAGTACCTACTTCATGAGGTTGTTGTGATGGTTAAATCATTAATACCTCTTGCTACTCAAGTCTATTCAGTTCCCAATTTTAGATAACAGAGACACCTACCCATGAAGGGTGCTTACAACACTGTCTGGAACACAGTAAGTCTACACGTGTTTGCTATAGTTACACCTAACTTAGCATACCCCAAGTCAACAGCATCTCTGCAACATTCCCCACCCTGCTCCAATGCCCATCTTCCCTGTCTTTGATGAATGATCACCAAGCCCGCCAGACACTAAAAGCAAACCCTTGGAGTTACTCAGACTCATTTATTCATTCAGCAACTATTGAGCACTGAAGATGTTCAAGGTATCCTGGTAGAAGACAGAATGGTGAACAAGACAAGCAGTCCCTGCTCTCAAATTGCCTATAGTCCAATGACAGACAAGCAAATTGTCAAAAATAATGTGCTATGTGCTATCCCCACCAGGACCTAACAGATCTCACATCTGTTTCCAATTTAGGTTCTCATCAATGTACGTTTAGACAATTACAACAGCCCTCCTGTCTGGTCTCCCTATTCTCAGTCTCTCCTTCAACTCCTTCTTCACACTGTAGCCAAACAAAGTGACTACAAGTCTGATCCCATCACCTACCTGTTTAAAAATCCCAAATATGGGCCAGACGCAGTGGTTCATGCCTATAATCCCAGCACTTTGGGAGGACGAGGCGGGTGGATCACCTGAGTTCGGGAGTTTGAAACCAGCCTGACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAATTAGCCTGGTGTGGTGGCACATGCCTGTAATCCCAGCTACTCGGGAGACCGAGGCAGTAGAATTGCTTGAACCCGGGAAGCAGAGGTTGCGGTGAGCCGAGATTGTGCCATTGCACTCCAGCCTGGGCAATAAGAGGGAAACCCCGTTTCAAAAAAAAAAAAAAAAATCCCAAATACGGCCAGGCGTGGTGGCTCACACCTGTAATCCCAACACTTTGGTAGCCTGAGGCGGGTGGATTACCTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACATGGCAAAACCCTGTCTCTACTAAAAATACAAAAATTAGCCAGGTGTGGGGGCAGGCACCTGTAGTCCTAGCTACTTGGGAGGCTGAGGCAGAAGAATCACTTGAACCTGGGAGGTAGAGGTTGCCGTAAGCTGAAATCATGCCACTACACTCCAGCCTGGGCAACAGAGTGAGACTCCGTCTCAAAACTAAATAAATAAATAAAATAAAAATCCCAAATACCTAGGAAGTCAGCTGATAAAGGCATAGGCTGAAGCTATATGGCCTGGGTTCAATTTCTAGCCCTGCTTCTTTTTTTTTTTTTTTTTTTTTTTTTTGAGATAGAGTTTTGCTCGTCACCTAGGCTAGAGTATAGTGGTGTGATCTTGGCTCACTGCAACCTCTGCCTCCCAGGTTCAAGTGAGTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCGTCCACAACCGTGCCCAGCTAATTTTTGTATTTTTGGTAGAGATGGGGTTTCACCATGTTGCCCAGGCTGGTCTTGAACTCCCGACCTCAGGTGATCCACCTGCTTTGGTCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCACGCCTGGCCTCTAGCTCTGCTTCTTACACACTGTGTGTCCTTGGGCAAATTATTTAACTGGTTTGTGTCCTATATTTATCCATATGCAATACAGGGATAATATTAAAACCTACAACCTATGGTTGTTGAGAGGAATAAGTGAGATTATGCATATAAAGTGCTTAGAACAGGGCCTGGCATATAGAAAATACTTGATAAATGTTAGCTGTTACTATTTTCATTACCTTCATCACTATCATGGACTTGCTGGTTAACTTGGAAAAATCATTTAACCTGTATTTTCCTCACTAGTCCAAAGATCTGACCTTTGCCTATCTTTTAAAAGAATCAAGTAAAATAACAGGCTTTTTCCGGGCATGGTGGCTAACACATGTAATCCCAGCACTTTGGGAGGCTGAGGCGAGTGGATTACCTGAGGTCAGGAGTTCGAGAGCAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATACAAAAAAAAAAAAAAAAAAAATTAGCGGGGCGTGGTTGTGGGTGCCTGTGATCCCATCAACTTGGGAGGCTGAGGCAGGAGAATTGCTTGAACCCAGGAGGCAGAGGTTGCAGTGAGCCAAGATCACCCCATTGCACTCCAGCATGGGTGACAAGAGTGAAACTCCGTCTCAAAAAATAAATATGTACATAATAAAAACAGGCTTTTTAGAATAACACGCCCTCCAAAAGAACTTCTGATGGTTCGCTCTCACCTACAGAACAAAGCCCAGCTTTCAAGGTATTTGAACATTCAGCCCCTAACCCACCCTTCCAGGCTTCTCCTGCACCCTACAAACCAGCCACATAGAACCCCTTTCTTGTGCCTAGTAGAAGTGGTCATCATTGGTCATCTCTTTGCTTTGGTCATGAGGTCCCTTCAGTTTACATTGTCTTTCCCATTTTCTCCCAAACATCTATCAAGCTTGTCCAACCTCCAGCCCAGGGACCACATGCAGCCAAGGACGGCTTGGAATACAGCCCGACACAAATTCATAAACTTTCTTAAAACATTATGAGATTTTTTCACATTTTTTTTTTTTAGCTTATCAGCCATCGTTAGTGTTCGTATATTTTATGCATGGCCCAAGACAATTCTTCTCCCAGTGTGGCTCAGGGAAGCCAAAAGATTGGAGACCCCTGATCTAAATACTCCATGTACATGAAGGTCACTTTCACTGCTGTTTCTTCCCAGAAATGTCTAGGTCCTTCAGGTAGAAGTAATCTTTTTCTTCTTGTAATTATTTTTATGTTCTTTTTAATCCTAGCTTCTGAGGCCTATAAGGTTAAACTGTTCTCATCTTCATGGAATTGTTCAGTAGAGTAAAAACAGTATGCAATTTCACTTAGTTTGTCAAAATCCAGAAACATACTTTTGAATTGTTAAAAAAAAAAAAAAAGATCCACAGGCTGGGCACAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCCGGTGGATCACCTGAGGTTGGGAGTTTGAGACCAGACTGGAGAAACCCCGTCTCTACTAAAAATACAGAATTATCCGGGCATGGTGGCACACGCCTGTAATCACAGCTGCTTGGGAAGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCGGAGGTTGTGGTGAGCCGAGATCATGCCATTGCCCTCCAGACTGGGCAACAAGAGCAAAACTTGATCTCAAAAAAAAAAATCCATAGAATTAATAAACAAAACCTGGCTGGGCAGGGTGGCTCAGACTTGTAATCCCAGTACCTTGGGAGGCTGAGGTGGGAGGATCACTTGAACCCAGCAGTTTGAGACCAGCCTGGGCAACATAGCAAGACCCCATCTCTATTTAAAAGAAAAAATTTAAAAAAATAATAAACAAGACCTAAAGGTTTTACAGTTTAACTCTTTTTTTTTTTTTTTTTTTTTTGGAGACAGGGTCTCACTCTGTCACCCATCAAAGGTGCAATCCTCCCAACACAGCCTCCCGAGTAGCTGGGACCATAGGTACATGCCACGACACCCAACCTTTTTTTTTTTTTTTTTTTTTTTGAGACAGTTTCACGCTTGTTGCCCAGGCTGGAGTGCAGTGGCATGATCTTGGCTCACTGCAACCTCCGCCTCCCAGGTTCAAGCAATTCTCTTGCCTCAGCCTTCCGAGTAGCTGGGATTACAGGCATGCACCACCATGCCTGGCTAA-T	MHC class I deficiency 3	Pathogenic (Aug 15, 2002)	7606
6-33303976-G-A	MHC class I deficiency	Likely benign (Aug 16, 2022)	1667187
6-33303981-G-A	MHC class I deficiency	Likely benign (Feb 10, 2022)	1607876
6-33303993-T-TG	MHC class I deficiency	Benign (Jan 31, 2023)	2832250
6-33304003-T-C	MHC class I deficiency	Benign (Jan 29, 2024)	1169190
6-33304111-G-T	MHC class I deficiency	Likely benign (Jun 10, 2023)	2995529
6-33304117-C-G	MHC class I deficiency	Likely benign (Oct 31, 2022)	2135236
6-33304120-A-G	MHC class I deficiency	Likely benign (Aug 01, 2023)	1128319
6-33304121-CACTT-C	MHC class I deficiency	Uncertain significance (Dec 13, 2023)	649689
6-33304131-C-T	MHC class I deficiency • not specified	Uncertain significance (May 14, 2024)	1426651
6-33304136-C-G	MHC class I deficiency	Uncertain significance (Jan 29, 2023)	2155960
6-33304144-C-T	MHC class I deficiency • TAPBP-related disorder	Benign (Jun 03, 2021)	730560
6-33304149-A-G	MHC class I deficiency	Uncertain significance (Jul 21, 2022)	1722289
6-33304160-A-G	MHC class I deficiency	Uncertain significance (Jan 31, 2020)	1042974
6-33304170-C-T	MHC class I deficiency	Uncertain significance (Sep 02, 2021)	534708
6-33304176-G-A	MHC class I deficiency • TAPBP-related disorder	Benign (Jan 31, 2024)	466397
6-33304180-A-G	MHC class I deficiency	Likely benign (Aug 23, 2022)	1544466
6-33304189-G-A	MHC class I deficiency • TAPBP-related disorder	Benign (Jan 29, 2024)	466396
6-33304194-C-T	MHC class I deficiency	Likely benign (Jan 04, 2024)	534736
6-33304200-G-A	MHC class I deficiency	Likely benign (Jan 12, 2024)	763120
6-33304201-G-A	MHC class I deficiency	Likely benign (Jan 19, 2024)	2709188
6-33304214-A-T	MHC class I deficiency	Uncertain significance (Dec 13, 2019)	843381
6-33304223-A-T	MHC class I deficiency	Uncertain significance (Aug 16, 2023)	1045689

GnomAD

Source: gnomAD

Gene	Type	Bio Type	Transcript	Coding Exons	Length
TAPBP	protein_coding	protein_coding	ENST00000426633	7	14694

pLI Probability LOF Intolerant	pRec Probability LOF Recessive	Individuals with no LOFs	Individuals with Homozygous LOFs	Individuals with Heterozygous LOFs	Defined	p
6.60e-9	0.440	125637	1	110	125748	0.000441

	Z-Score	Observed	Expected	Observed/Expected	Mutation Rate	Total Possible in Transcript
Missense	0.764	258	295	0.875	0.0000154	3156
Missense in Polyphen		81	97.312	0.83237		1081
Synonymous	0.977	113	127	0.890	0.00000677	1144
Loss of Function	0.949	15	19.5	0.768	0.00000105	182

LoF frequencies by population

Ethnicity	Sum of pLOFs	p
African & African-American	0.00116	0.00115
Ashkenazi Jewish	0.00	0.00
East Asian	0.000109	0.000109
Finnish	0.0000522	0.0000462
European (Non-Finnish)	0.000605	0.000580
Middle Eastern	0.000109	0.000109
South Asian	0.000262	0.000261
Other	0.000332	0.000326

dbNSFP

Source: dbNSFP

Function: FUNCTION: Involved in the association of MHC class I with transporter associated with antigen processing (TAP) and in the assembly of MHC class I with peptide (peptide loading). {ECO:0000269|PubMed:10636848}.;
Disease: DISEASE: Bare lymphocyte syndrome 1 (BLS1) [MIM:604571]: A HLA class I deficiency. Contrary to bare lymphocyte syndromes type 2 and type 3, which are characterized by early-onset severe combined immunodeficiency, class I antigen deficiencies are not accompanied by particular pathologic manifestations during the first years of life. Systemic infections have not been described. Chronic bacterial infections, often beginning in the first decade of life, are restricted to the respiratory tract. {ECO:0000269|PubMed:12149238}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway: Antigen processing and presentation - Homo sapiens (human);Immune System;Adaptive Immune System;Antigen processing-Cross presentation;Class I MHC mediated antigen processing & presentation;ER-Phagosome pathway;Antigen Presentation: Folding, assembly and peptide loading of class I MHC (Consensus)

Intolerance Scores

loftool: 0.977
rvis_EVS: 0.13
rvis_percentile_EVS: 63.49

Haploinsufficiency Scores

pHI: 0.0691
hipred: N
hipred_score: 0.257
ghis: 0.536

Essentials

essential_gene_CRISPR: N
essential_gene_CRISPR2: N
essential_gene_gene_trap: N
gene_indispensability_pred: E
gene_indispensability_score: 0.992

Gene Damage Prediction

	All	Recessive	Dominant
Mendelian	Medium	Medium	Medium
Primary Immunodeficiency	Medium	Medium	Medium
Cancer	Medium	Medium	Medium

Mouse Genome Informatics

Gene name: Tapbp
Phenotype: immune system phenotype; hematopoietic system phenotype;

Gene ontology

Biological process: MHC class Ib protein complex assembly;antigen processing and presentation of peptide antigen via MHC class I;antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent;retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum;immune response;regulation of gene expression;antigen processing and presentation of endogenous peptide antigen via MHC class I;amide transport;peptide antigen stabilization;regulation of protein complex stability;protein-containing complex assembly;vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane
Cellular component: Golgi membrane;endoplasmic reticulum;endoplasmic reticulum membrane;integral component of membrane;phagocytic vesicle membrane;endoplasmic reticulum-Golgi intermediate compartment membrane;MHC class I peptide loading complex;integral component of lumenal side of endoplasmic reticulum membrane
Molecular function: protein binding;peptide antigen-transporting ATPase activity;MHC class I protein binding;peptide antigen binding;TAP1 binding;TAP2 binding;unfolded protein binding;TAP complex binding